E. P. Hui

Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms (2009)

Ma, B. B. Y., Hui, E. P., Wong, S. C. C., Tung, S. Y., Yuen, K. K., King, A., ...

Background: Nasopharyngeal carcinoma (NPC) is a platinum-sensitive cancer and excision repair cross-complementing group 1 (ERCC1) polymorphisms have been shown to predict survival in several cancers...

CD4+ T-Cell Responses to Epstein-Barr Virus Nuclear Antigen EBNA1 in Chinese Populations Are Highly Focused on Novel C-Terminal Domain-Derived Epitopes

Tsang, C. W., Lin, X., Gudgeon, N. H., Taylor, G. S., Jia, H., Hui, E. P., ...

Epstein-Barr virus nuclear antigen EBNA1, the one viral protein uniformly expressed in nasopharyngeal carcinoma (NPC), represents a prime target for T-cell-based immunotherapy. However, little is...

CD4+ T-Cell Responses to Epstein-Barr Virus Nuclear Antigen EBNA1 in Chinese Populations Are Highly Focused on Novel C-Terminal Domain-Derived Epitopes

Tsang, C. W., Lin, X., Gudgeon, N. H., Taylor, G. S., Jia, H., Hui, E. P., ...

Epstein-Barr virus nuclear antigen EBNA1, the one viral protein uniformly expressed in nasopharyngeal carcinoma (NPC), represents a prime target for T-cell-based immunotherapy. However, little is...